The NLRP3 inflammasome: the hidden driver of macular degeneration

Age-related macular degeneration is not merely a problem of retinal wear; it is fundamentally a disease driven by uncontrolled chronic inflammation in the eye. The NLRP3 inflammasome, a critical component of innate immunity, acts as a central integrator of retinal stress signals, activating through multiple pathways—canonical, noncanonical, and alternative—that trigger forms of inflammatory cell death including pyroptosis and PANoptosis. The mechanism behaves differently depending on which retinal cell type is affected and the disease stage: it amplifies inflammation in early and intermediate AMD but promotes retinal atrophy in geographic atrophy and angiogenic signaling in neovascular AMD. Current anti-inflammatory therapies work by sabotaging the inflammasome's controlling mechanisms rather than removing their underlying causes—an approach that functions but risks compromising necessary inflammatory defenses alongside pathological inflammation. Emerging therapies targeting the NLRP3 pathway face substantial challenges in cell-type specificity, retinal drug delivery, and long-term safety, yet they represent a promising window to halt blindness in aging populations without waiting for complete tissue rejuvenation.